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ABSTRACT 
 
Aims: To investigate the probability of developing type 2 diabetes mellitus (T2DM) at different 
body mass index compared to matched non-diabetic controls in a multi-ethnic population. 
 
Materials and Methods:  Case-control study of 90,367 patients with incident diabetes and 
362,548 age-sex-ethnicity matched controls from UK primary care. Probability of 
developing T2DM was estimated.  
 
Results: Case and control patients were 56 years old at index and 56% were male. Patients 
with T2DM had significantly higher mean BMI level by about 5 kg/m2 at diagnosis (32.2 
kg/m2) ,compared to the matched controls (27.4 kg/m2). White European (n=79,270), African-
Caribbean (n=4,115) and South Asians (n=7,252) were 58, 48, and 46 years old with mean 
BMI of 32.5, 31.1, 29.2 kg/m2 respectively at diagnosis. More South Asians developed T2DM 
at BMI below 30 kg/m2 (38%) than White Europeans (26%) and African-Caribbeans (29%), 
(all p<0.01). Within the 18-70 year age range, South Asian male and female had significantly 
higher probability of developing diabetes in the continuously measured BMI range of 18-30 
kg/m2, compared to White Europeans and African-Caribbeans. Across all age groups < 70 
years, South Asians and African-Caribbeans had significantly higher probability of developing 
T2DM in the normal weight and overweight categories, compared to White Europeans.  
However, this risk patterns of developing diabetes was reversed amongst the obese at all age 
groups.  
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Conclusion: Risk patterns of developing diabetes at different levels of obesity varies between 
ethnic groups across all age groups, while South Asians and African-Caribbeans carry the 
highest risk at younger age and at lower adiposity burden.   
 
 
 
Key Words: Body Mass Index, Probability of Developing Type 2 Diabetes, Matched Case-
control Study, Multi-ethnic Comparisons 
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INTRODUCTION 
Obesity [body mass index (BMI) ≥ 30 kg/m2] is a worldwide epidemic affecting people of all 
ages, and is a major risk factor for type 2 diabetes mellitus (T2DM) and cardiovascular diseases 
(CVD) [1]. Current epidemiological indices of obesity have doubled since 1980, with about 
13% of the world’s population being obese as of 2014 [1, 2]. Some population-based studies 
have been conducted to assess the impact of BMI classification, including overweight and 
various grades of obesity, on the risk of T2DM [3-5]. The BMI cut-points of 25 kg/m2 and 30 
kg/m2 were defined as the basis for identifying overweight and obesity based on 
epidemiological studies investigating association with mortality and morbidity, primarily in 
White population. However, there is increasing evidence that levels of risk associated with the 
classification of overweight and obesity vary across ethnic groups [6-11].  
 
Propensity to develop T2DM varies considerably between ethnic groups and identifying the 
BMI cut points within specific ethnic groups at which the risk of T2DM increases is useful to 
inform public health policy. Some studies have evaluated the ethnicity-specific diabetes 
incidence rates in association with prior BMI levels using population level and primary care 
data [7, 9, 12, 13]. These studies were limited by the number of subjects in the non-white ethnic 
groups. The pooled analysis of survey data from various countries conducted by the DECODE-
DECODA study group in 2003 evaluated the association of ethnicity, BMI and prevalence of 
T2DM [13]. However, the BMI measurements were not consistently taken at the time of 
diagnosis of diabetes. Only one previous study has compared the distribution of BMI at 
diagnosis of T2DM with non-diabetic controls [5]. Ganz and colleagues defined BMI at 
diagnosis as the last measurement of BMI taken within one year prior to diagnosis of T2DM, 
and randomly matched controls to cases [5]. While this study reported increased risk of 
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developing T2DM with higher BMI levels, the differential aspects of ethnicity in the 
relationship between BMI and risk were not addressed.  
 
No study has compared the distribution of BMI at diagnosis of T2DM by ethnicity with non-
diabetic controls. In addition, we are not aware of any population-based study evaluating 
differences in the risk of developing T2DM in men and women in different age levels between 
different ethnic groups over the whole spectrum of BMI distribution at diagnosis. Using a large 
cohort of incident T2DM patients, and an age-sex-ethnicity matched non-diabetic control 
cohort from United Kingdom primary care, the aims of this study were to evaluate for each 
ethnic group (1) the distribution of BMI, glycaemic, and vascular risk factors at diagnosis of 
T2DM, and (2) the probability of developing T2DM over the entire spectrum of BMI and age.  
 
 
MATERIALS AND METHODS 
Data source 
Data for this study were obtained from The Health Improvement Network (THIN) database, a 
large anonymised longitudinal dataset derived from a network of more than 600 primary care 
providers across the United Kingdom.  With longitudinal data on approximately 11 million 
individuals registered with the primary care system, the THIN database has been extensively 
used for academic research in various disciplines [14]. The accuracy and completeness of this 
database has been previously described [15, 16]. Notably, the database has similar distribution of 
major chronic diseases including diabetes, heart failure and obesity when compared to UK 
national statistics [16, 17]. Clinically diagnosed diseases are recorded using Read codes [18] and 
with each diagnosis, an event date is entered. THIN database provides comprehensive patient-
level longitudinal information on demographic, anthropometric, clinical and laboratory 
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measures, clinical diagnosis of diseases / events, along with complete information on 
prescriptions for medications with dates and doses. Formal access to the database has been 
obtained and the Scientific Review Committee of the THIN database, UK (reference number: 
15THIN030).  
 
 
Identification of T2DM cases 
Patients with T2DM were identified through various steps of clinically guided iterative 
processes. Specifically, the T2DM cases were selected if: 
(i) Patient had a record of Read code related to T2DM,   
(ii) Patient from step (i) above had received at least one prescription for an antidiabetic 
drug in addition to the clinical diagnosis, or  
(iii) Patient in step (i) above had received a lifestyle modification intervention.  
A set of 345,013 patients with newly diagnosed T2DM (from January 1990 to September 
2014) was identified, who had complete information on age at diagnosis (≥18 years) and sex. 
Of these patients only 90,754 patients had their ethnicity identified as White European, 
African-Caribbean or South Asian, (Supplementary Figure 1). South Asians were defined as 
patients with Indian, Pakistan, Sri Lanka, and Bangladesh origin while African-Caribbeans 
were defined as patients with Black-African and/or Caribbean origin. White Europeans were 
patients with self-reported ethnicity as White, European, Caucasian, and/or New Zealand 
European.  
 
Development of control subjects  
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A control pool of patients without T2DM was obtained by selecting individuals who had no 
diagnosis of any type of diabetes and had never received an antidiabetic prescription. Exact 
matches based on ethnicity, age, and sex were obtained from these pool of potential controls 
without replacement. To the 90,637 eligible T2DM cases with identified three ethnic groups, 
362,548 controls were successfully matched in a 1:4 ratio. Index date for controls was defined 
as the date of the diabetes diagnosis for their matched cases.   
 
The following information on index date was extracted for all patients where available: 
smoking status, deprivation score, weight, BMI, glycated haemoglobin (HbA1c), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), low density lipoproteins (LDL-C), high 
density lipoproteins (HDL-C), and triglycerides. All available measures on or within 3 months 
prior to the index date were considered as the baseline measures. Anti-glycaemic agents, anti-
hypertensive agents, cardio-protective medications (CPM), weight lowering drugs and anti-
depressants were also obtained along with dates of prescription. The CPMs were defined as 
use of statins or angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers 
or beta blockers on or before diagnosis. BMI categories were defined following WHO 
established criteria [19] as follows: normal weight (18.5-24.99 kg/m2), overweight (25-29.99 
kg/m2), Grade 1 obese (30-34.99 kg/m2), Grade 2 obese (35-39.99 kg/m2) and Grade 3 obese 
(≥ 40 kg/m2).In addition, records of cardiovascular diseases (CVDs), renal diseases and cancer 
on or before index date were also obtained.  A composite variable for CVD (any CVD) was 
defined as the occurrence of angina or myocardial infarction or coronary artery disease 
(including bypass surgery and angioplasty) or heart failure or stroke before diagnosis.   
 
Statistical analysis 
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Basic characteristics of incident T2DM patients and their matched non-diabetic control 
population, separately for ethnic group, were summarized using number (%), means ± SD or 
median (first quartile, third quartile) as appropriate. Differences between patients with T2DM 
and their matched controls were evaluated using rank sum test for continuous variables and the 
chi-squared for binary data. The distributions of BMI at diagnosis of T2DM in three different 
ethnic groups were compared using analysis of variance models, separately for different age 
groups at diagnosis.  
To explore the association of BMI at diagnosis with the risk of developing T2DM, in 
interaction with different ethnic groups, multivariate logistic regression models were fitted. 
The covariates for adjustments were age, sex, smoking status, deprivation score, and the history 
of CVD, cancer, and chronic kidney disease (CKD) on or prior to the index date. The 
probability of developing T2DM over the whole distribution of BMI in different ethnic groups 
was evaluated, using both continuous measure of BMI and the World Health Organisation 
defined categories of BMI. To explore the possible differences in the patterns of association of 
BMI with the risk of developing T2DM in different ethnic groups for male and female, and 
also over different age groups at index date, separate adjusted models were fitted. The 
differences in predicted probabilities between ethnic groups were calculated using the 
methodology described by King and colleagues (2000) [20] and Zelner (2009) [21]. The estimated 
probabilities and the 95% confidence intervals were presented as appropriate. Sensitivity 
analyses to support the above analyses include (1) an extended model incorporating measures 
of SBP, LDL-C, HDL-C and triglyceride at index, the use of CPMs, weight lowering drugs, 
anti-hypertensives, and anti-depressants before diagnosis, and (2) comparison of distribution 
of BMI and HbA1c at diagnosis for patients diagnosed after 01 Jan 2006. 
 
RESULTS 
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The basic demographic and clinical profiles of 90,367 patients with T2DM and 362,548 age-
sex-ethnicity matched controls, separately for ethnic groups, are shown in Table 1. Case and 
control patients were 56 years old at index and 56% were male. Patients with T2DM had 
significantly higher mean BMI level by about 5 kg/m2 at diagnosis (32.2 kg/m2) , compared to 
the matched controls (27.4 kg/m2). However, this difference was smaller in the African-
Caribbean (2.4 kg/m2) and South Asians (2.8 kg/m2). Furthermore, cases were more likely to 
receive anti-hypertensives, cardio-protective medications, and anti-depressants and were more 
likely to have any CVD before diagnoses than controls. South Asians were more likely to 
develop diabetes at a significantly lower age (mean age 46 years, 31% below 40 years) 
compared to the White Europeans (mean age 58 years, 9% below 40 years) and African-
Caribbeans (mean age 48 years, 23% below 40 years). Compared to male patients, females 
developed T2DM at a significantly higher BMI level across all ethnic groups. More South 
Asians developed T2DM at BMI below 30 kg/m2 (38%) than White Europeans (26%) and 
African-Caribbeans (29%), (all p<0.01). Those not included in the study because of non-
availability of ethnicity data were older (mean age 61 years compared to 56 years in the study 
cohort), but had similar distribution of sex, BMI, current smokers, ex-smokers, and never 
smokers. 
 
The average SBP in South Asians at the time of diagnosis of T2DM (132 mmHg) was 
significantly lower with only 20% having SBP ≥ 140 mmHg, compared to the two other ethnic 
groups (p<0.01). Among those who developed T2DM, only 28% of South Asians were current 
or ex-smokers at index date, compared to 60% and 33% in the White and African-Caribbean 
ethnic groups respectively. African-Caribbean and South Asians had significantly higher LDL-
C levels at diagnosis of T2DM (LDL-C ≥ 100 mg/dl: 34% and 28% respectively) compared to 
the White Europeans (LDL-C ≥ 100 mg/dl: 23%, Table 1).   African-Caribbean patients had 
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significantly higher mean HbA1c level at diagnosis [9.1% (76 mmol/mol), 30% with HbA1c ≥ 
7.5 %( 58 mmol/mol)] compared to South Asians [8.5% (69mmol/mol), 28% with HbA1c ≥ 
7.5% (58 mmol/mol)] and White Europeans [8.2% (66 mmol/mol), 22% with HbA1c ≥ 7.5% 
(58 mmol/mol].  
 
The distributions of BMI at diagnosis of T2DM in different ethnic groups, by age groups at 
diagnosis, are presented in Table 2. South Asians and African-Caribbeans aged 18-70 years at 
diagnosis developed T2DM at significantly lower BMI than White Europeans. Over the whole 
distribution of BMI level, the probability of developing T2DM in South Asians compared with 
other ethnic groups, separately for male and female and by different age groups, are presented 
in Figure 1 and Figure 2 respectively. When analysed with continuous measure of BMI, 
compared to both White Europeans and African-Caribbeans, South Asians had a significantly 
higher probability of developing T2DM within the range of BMI from 18 kg/m2 to about 30 
kg/m2, for both male and female (Figure 1 A-D). The adjusted probability (95% CI) of 
developing T2DM at different BMI category levels compared between the three ethnic groups, 
separately for different age groups, are presented in Supplementary Figure 2. Across all age 
groups within the age of 70 years, South Asians and African-Caribbeans had significantly 
higher probability of developing T2DM in the normal weight and overweight categories, 
compared to White Europeans. Sensitivity analysis with extended list of covariates revealed 
similar results.  
 
Given the different patterns of risk of developing T2DM among obese patients between ethnic 
groups across different age groups (Supplementary Figure 2), we evaluated the odds of 
developing T2DM in African-Caribbeans and South Asians, compared to White Europeans, 
separately for each age group. Within each age group, the probability of developing T2DM 
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was greater amongst South Asians at lower BMI. This relationship was reversed at higher BMI 
levels and compared to White Europeans, the South Asians had 22% (95% CI of OR: 
0.65,0.95), 30% (95% CI of OR: 0.62,0.81), 24% (95% CI of OR: 0.65,0.88) and 39% (95% 
CI of OR: 0.48,0.77) lower odds (adjusted) of developing T2DM in the age groups ≤ 40, 41-
50, 51-60 and 61-70 years respectively.   African-Caribbean patients had 43% (95% CI of OR: 
0.45, 0.73), 43% % (95% CI of OR: 0.50, 0.66), 33% (95% CI of OR: 0.57, 0.78) and 35% 
(95% CI of OR: 0.52, 0.82) lower adjusted odds of developing T2DM in the respective age 
groups. However, these odds were not statistically significantly different between African-
Caribbeans and South Asians (Supplementary Table 2).  
 
DISCUSSION 
This case-control study with a large number of White European, South Asian and African-
Caribbean individuals from a nationally representative primary care database reveals 
significantly different (1) distributions of body weight, BMI and other cardiovascular risk 
factors at the time of diagnosis of T2DM and (2) probability of developing T2DM over the 
whole spectrum of BMI, in interaction with age and sex. This study also reveals that the risk 
patterns of developing diabetes at different levels of obesity varies between ethnic groups 
across all age groups. To the best of our knowledge, this is the first study exploring the 
variations in T2DM risk over the whole distribution of BMI at the time of diagnosis across the 
South Asian, African-Caribbean and White European populations.   
 
Our findings confirm the association of increased risk of T2DM with increasing BMI. More 
importantly, it adds to the evidence that for any given age, South Asians have a greater risk of 
T2DM at lower BMI. Typically, African-Caribbeans and South Asians in our study were 
significantly younger and had a distinct metabolic risk profile compared to White Europeans 
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characterised by lower body weight, systolic blood pressure, and lower rates of smoking but 
significantly higher HbA1c levels. The observed higher HbA1c level in South Asians and 
African-Caribbeans is in line with earlier findings [22]. While different possible reasons, 
including ethnic differences in pre- and post-prandial glycaemia and glycation rate of 
haemoglobin have been postulated, no confirmatory mechanistic study has yet been reported 
on this aspect. At population level, evaluation of longitudinal patterns of pre- and post-prandial 
glucose changes along with the measures of insulin deficiency from pre-diabetes state may 
reflect some light on this issue. Based on a US population with 12,179 T2DM patients and 
25,177 controls, Ganz and colleagues (2014) reported a mean age and BMI of 55 years and 35 
kg/m2 respectively at diagnosis [5]. With similar age at diagnosis of T2DM, our UK study cohort 
had significantly lower BMI level (32 kg/m2). However, this distribution of BMI at diagnosis 
is consistent with other studies reporting BMI at diagnosis of T2DM in UK population [23-25] . 
Similarly, our finding that women developed T2DM at significantly higher BMI level 
compared to men across ethnicity is consistent with earlier reports [26, 27]. Earlier studies have 
shown that the onset of T2DM occurs up to a decade early amongst South Asians. A Canadian 
cohort based diabetes incidence study reported that the median age at diagnosis was lowest 
among South Asians (49 years), followed by African-Caribbeans (57 years), and Whites (58 
years) [9]. Our data is consistent with these observations and on average South Asians were 12 
years younger at diagnosis compared to their White European counterparts. Factors that 
influence the predisposition of South Asians to develop T2DM at  younger are largely unknown 
and may  be related to a combination of  genetic  and environmental factors that have not yet 
been fully characterised [26, 27]. 
 
Ganz and colleagues (2014) reported significantly increasing odds of developing T2DM with 
increasing BMI [5]. While this study also evaluated the risk of developing T2DM in various age 
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groups using additive models, the interaction of age and body weight in the risk of developing 
T2DM was not explored. Given that age and obesity are two major risk factors for T2DM, we 
explored the interaction of age and BMI levels (separately for male and female) in evaluating 
the risk of developing T2DM across the three ethnic groups. One of the novelties of this study 
is comparative exploration of the probability of developing T2DM over the whole continuous 
distribution as well as categories of BMI by ethnic groups. When BMI was analysed as a 
continuous variable, we found that South Asians aged 40 years and above had a significantly 
greater probability of T2DM at lower BMI levels (18-30kg/m2) compared to the other two 
ethnic groups. When analysed with BMI as a categorical variable, the higher probability of 
T2DM for South Asians with lower BMI extended from those younger than 40 years to those 
less than 70 years age.  This difference in observed probability of developing T2DM using 
continuous BMI versus BMI categories is reflective of the fact that there is loss of statistical 
information when converting a continuous variable to a categorical variable. Interestingly, in 
both the analyses, we identified a distinct pattern of risk between South Asians and White 
Europeans with probability of T2DM being greater at lower BMI for South Asians and at higher 
BMI for White Europeans.  
 
Earlier ethnicity specific studies evaluating association of prior BMI with the incident rates of 
T2DM reported higher risk in South Asians at a lower BMI level [7, 9, 28]. During a median 
follow-up of 6 years, Chui and colleagues reported higher T2DM incidence rates T2DM in 
South Asians at lower ages and BMI compared to the White Europeans [9]. Similar observation 
was made in another follow-up study reported by Tillin and colleagues [7]. Our study elaborates 
on the significantly higher likelihood of developing T2DM at lower BMI levels among South 
Asians, compared to White Europeans and African-Caribbeans. We have also identified a 
significant change in the risk pattern at higher BMI levels while compared between ethnic 
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groups at different age levels (Supplementary Figure 2 and Figure 2). Additionally, our study 
provides detailed information on the contrasting probability of developing T2DM at different 
age groups and ethnicity across the entire spectrum of BMI. There are several possible 
explanations for this contrasting effects of obesity on probability of diabetes between ethnic 
groups. While BMI is an accepted measure of obesity, it does not differentiate between patterns 
of obesity (visceral v sub cutaneous). It is well known that South Asians have excess visceral 
adiposity even at lower BMI and that may explain the higher propensity of South Asians to 
develop T2DM at lower BMI. However, that pattern would be expected to persist even at higher 
levels of BMI and therefore South Asians would be expected to have a greater risk in 
comparison with White Europeans for any level of BMI. Our observation that this difference 
is only evident at lower BMI but not at higher BMI range would suggest that the excess visceral 
adiposity alone does not explain this variance. An alternative explanation could be that relative 
contribution of obesity to the risk of T2DM may be greater amongst White Europeans 
compared to that in South Asians and that the risk of T2DM in South Asians may additionally 
be determined by underlying beta cell dysfunction. Clearly, this needs to be addressed in future 
studies.   
  
The strength of this study is that it includes a large number of T2DM patients from a primary 
care system with a large number of South Asians; a representative age and sex matched non-
diabetic control cohort; use of anthropometric, clinical risk factor measures at index date; and 
a robust analysis approach to explore the potential interactions between age, sex and BMI in 
different ethnic groups. Patient-level data from electronic health records present challenges in 
terms of accuracy and completeness of the study variables of interest. The limitations of this 
study include: (1) availability of ethnicity data on a limited number of patients, (2) missing risk 
factor data, (3) potential for residual confounding, and (4) inability to draw a causal link 
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between BMI and T2DM, as with all observational studies. However, ethnicity recording for 
South Asians and African-Caribbeans in the electronic database used for this study is 
comparable to the general population of UK [29]. We also attempted to minimize bias introduced 
by confounders through the use of multivariate models with a detailed list of possible 
confounders. However, unavailability of information on education, physical activity, diet, and 
other risk factors may have introduced bias into the risk estimates.  
 
To conclude, the South Asian and African-Caribbean populations have an increased burden of 
T2DM with its complications. In this large case control data analysis we have demonstrated 
that T2DM occurs in South Asians at least 12 years earlier with mean age 46 years, when 
compared to White Europeans, with about a third developing under the age of 40 years. We 
believe the early presentation of diabetes in this ethnic population contributes to the glycaemic 
load and the burden of complications. Hence, the early diagnosis of diabetes, recognising the 
lower age of presentation may help to ameliorate the glycaemic burden and to do this a lower 
age cut-off for screening in national programmes for South Asians is required. This is the first 
large cohorts that we are aware of in which it has been demonstrated that South Asians develop 
diabetes at a mean lower BMI by 5 kg/m2 when compared to White Europeans. This has 
implications both in terms of diagnosing obesity in South Asians along with appropriate 
management interventions.   
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FIGURE LEGENDS 
Figure 1:  The association between BMI at diagnosis and risk of T2DM (95% CI) compared 
between three groups of ethnicity. [A: Adjusted probability of developing T2DM (95% CI) at 
different levels of BMI for male South Asians, compared to male White Europeans; B: 
Adjusted probability of developing T2DM (95% CI) at different levels of BMI for female 
South Asians  compared to female White Europeans ; C: Adjusted probability of developing 
T2DM at different BMI levels for male South Asians compared to male African-Caribbean; D 
: Adjusted probability of developing T2DM at different BMI levels for female South Asians 
compared to female White Europeans ;  Probability estimated in Figures 1A, 1B, 1C, & 1D 
are adjusted for age, smoking status, deprivation score, and history of CVD, cancer and 
CKD on or prior to the index date.  ]. 
 
Figure 2:  Adjusted probability of developing T2DM (95% CI) across levels of BMI for 
different age groups. [A: South Asians compared to White Europeans; B:South Asians 
compared to African-Caribbeans ;Estimated  are adjusted for sex, smoking status, 
deprivation score, and history of CVD, cancer and CKD on or prior to the index date; SA: 
South Asian; WE: White European; AC: African-Caribbean]. 
 
Supplementary Figure 1: The identification of T2DM study cohort and their matched controls 
from THIN database. [1: T2DM Read code + (antidiabetic medication or lifestyle modification 
intervention, excludes patients with any other type of diabetes (eg. Type 1 diabetes, Gestational 
diabetes); 2: Age at index date greater or equal to 18, complete information on gender and 
ethnicity (White European, African-Caribbean and South Asian only]; 3 Excludes patients who 
have ever received anti-hyperglycaemic drugs.  
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Supplementary Figure 2:  Adjusted probability of developing T2DM (95% CI) across levels 
of BMI categories for different age groups. [Adjusted for sex, smoking status, deprivation 
score, and history of CVD, cancer, and CKD on or prior to the index date; NW: Normal 
weight; OW: Overweight; G1O: Grade 1 Obese; G2O: Grade 2 Obese; G3O: Grade 3 
Obese]. 
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TABLES 
Table 1:  Distribution of basic characteristics of T2DM patients and their matched controls, stratified by ethnicity 
 
White European 
(N=396,350) 
African-Caribbean  
(N=20,575) 
South Asian 
(N=36,260) 
ALL  
(N=453,770) 
 T2DM Control T2DM Control T2DM Control T2DM Control 
Patients* 79,270 317,080 4,115 16,460 7,252 29,008 90,637 362,548 
Age at diagnosis (years) † 58 ± 12 58 ± 12 48 ± 12 48 ±12 46 ± 12 46 ± 12 56 ±  13 56 ± 13 
Age at diagnosis (years) ‡ 58 (49, 67) 58 (49, 67) 48 (40, 56) 48 (40, 56) 45 (38, 54) 45 (38, 54) 57 (47, 66) 57 (47, 66) 
Age group *         
≤40 6,724 (9) 26,896 (9) 949 (23) 3,796 (23) 2,204 (30) 8,816 (30) 9,877 (11) 39,508 (11) 
41-50 15,614 (20) 62,456 (20) 1,511 (37) 6,044 (37) 2,598 (36) 10,392 (36) 19,723 (22) 78,892 (22) 
51-60 22,425 (28) 89,700 (28) 1,007 (25) 4,028 (25) 1,529 (21) 6,116 (21) 24,961 (28) 99,844 (28) 
61-70 21,751 (27) 87,004 (27) 491 (12) 1,964 (12) 688 (10) 2,752 (10) 22,930 (25) 91,720 (25) 
71+ 12,756 (16) 51,024 (16) 157 (4) 628 (4) 233 (3) 932 (3) 13,146 (15) 52,584 (15) 
Male * 44,651 (56) 178,604 (56) 2,102 (51) 8,408 (51) 4,005 (55) 16,020 (55) 50,758 (56) 203,032 (56) 
Current smokers * 15,581 (20) 59,060 (19) 527 (13) 2,307 (14) 967 (13) 3,460 (12) 17,075 (19) 64,827 (18) 
Ex-smokers * 31,966 (40) 114,099 (36) 808 (20) 2,612 (16) 1,058 (15) 3,497 (12) 33,832 (37) 120,208 (33) 
Never smokers * 31,427 (40) 138,903 (44) 2,769 (67) 11,130 (68) 5,195 (72) 21,162 (73) 39,391 (44) 171,195 (47) 
Highest affluence * 3,391 (4) 15,054 (5) 564 (14) 1,954 (12) 665 (9) 2,525 (9) 4,620 (5) 19,533 (5) 
Lowest affluence * 16,923 (21) 56,124 (18) 994 (24) 4,290 (26) 1,852 (26) 7,073 (24) 19,769 (22) 67,487 (19) 
HbA1c (%) ,[mmol/mol] 
§ 8.2 ± 2.1 
[66 ± 23.0] 
 9.1 ± 2.7 
[76 ± 29.5] 
 8.5 ±  2.1 
[69 ± 23.0] 
 8.3 ± 2.1 
[67 ± 23.0] 
 
HbA1c ≥ 7.5%*
§ 17,730 (22)  1,234 (30)  2,021 (28)  20,985 (23)  
Weight (kg) † 92.2 ± 21.0 77.8 ± 16.8 88.3 ± 18.7 81.0 ± 16.2 78.8 ± 17.1 71.3 ± 14.6 91.0 ±  21.0) 77.5 ± 16.8 
Weight (kg) ‡ 90.0 (78, 104) 76.2 (66, 88) 86.0 (75, 99) 79.7 (70, 90) 76.0 (67, 88) 70.0 (61, 80) 88.9 (76, 103) 76.0 (66, 87) 
BMI (kg/m²) †   -- All  32.5 ± 6.8 27.4 ± 5.2 31.1 ± 6.2 28.7 ± 5.6 29.2 ± 5.7 26.5 ± 4.8 32.2 ± 6.8 27.4 ± 5.2 
BMI (kg/m²) †   -- Male  31.7 ± 6.0 27.5 ± 4.7 29.3 ± 5.3 27.3 ± 4.6 28.4 ± 5.4 26.2 ± 4.6 31.4 ± 6.0 27.4 ± 4.7 
BMI (kg/m²) †  -- Female 33.4 ± 8.0 27.4 ± 5.8 33.0 ± 6.6 30.0 ± 6.2 30.2 ± 5.8 26.6 ± 5.1 31.5 ± 6.8 27.0 ± 5.3 
BMI (kg/m²) ‡ 31.4 (28, 36) 26.8 (24, 30) 30.2 (27, 35) 28.0 (25, 32) 28.3 (25, 32) 26.0 (23, 29) 31.1 (28, 36) 26.8 (24, 30) 
Normal weight* 4,958 (6) 24,052 (8) 365 (9) 834 (5) 921 (13) 2,374 (8) 6,244 (7) 27,260 (8) 
Overweight* 15,439 (20) 30,135 (10) 820 (20) 1,283 (8) 1,830 (25) 2,376 (8) 18,089 (20) 33,794 (9) 
Grade 1 obese* 15,592 (20) 13,654 (4) 719 (18) 764 (5) 1,050 (15) 896 (3) 17,361 (19) 15,314 (4) 
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Grade 2 obese* 8,973 (11) 4,073 (1) 383 (9) 288 (2) 386 (5) 251 (1) 9,742 (11) 4,612 (1) 
SBP (mmHg) † 141 ± 19 136 ± 19 137 ± 19 133 ± 19 132 ± 18 128 ± 17 140 ± 19 135 ± 18 
SBP  ≥ 140 mmHg * 28,971 (37) 52,256 (17) 1,104 (27) 1,742 (11) 1,461 (20) 2,092 (7) 31,536 (35) 56,090 (16) 
DBP (mmHg) † 82 ± 11 80 ± 10 83 ± 11 81 ± 11 82 ± 11 79 ± 10 82 ± 11 80 ± 10 
LDL-C(mg/dl) † 117 ± 42 120 ± 40 126 ± 39 124 ± 35 119 ± 39 121 ± 35 117 ± 42 120 ± 39 
LDL-C ≥ 100 mg/dl* 17,944 (23) 25,328 (8) 1,388 (34) 1,531 (9) 2,003 (28) 2,684 (9) 21,335 (24) 29,543 (8) 
HDL-C (mg/dl)† 46 ± 14 56 ±17 48 ± 13 58 ± 17 44 ± 11 51 ± 14 46 ± 13 56 ± 17 
HDL-C ≤ 45 mg/dl* 19,024 (24) 11,941 (4) 924 (23) 501 (3) 2,041 (28) 1,452 (5) 21,989 (24) 13,894 (4) 
Triglycerides (mg/dl) ‡ 
159 
(122, 213) 
115 
(87, 159) 
115 
(81, 159) 
82 
(62, 115) 
151 
(115, 204) 
115 
(89, 168) 
159 
(115, 213) 
115 
(84, 159) 
Triglyceride ≥ 150 mg/dl* 18,654 (24) 13,323 (4) 601 (15) 260 (2) 1,681 (23) 1,316 (5) 20,936 (23) 14,899 (4) 
Complications*         
CKD (≥ stage 3) 1,752 (2) 4,493 (1) 52 (1) 146 (1) 34 (1) 143 (1) 1,838 (2) 4,782 (1) 
Cancer  4,746 (5) 18,793 (6) 100 (2) 278 (2) 68 (1) 339 (1) 4,914 (5) 19,410 (5) 
Myocardial Infarction 4,802 (6) 9,120 (3) 34 (1) 85 (1) 181 (3) 355 (1) 5,017 (6) 9,560 (3) 
Heart Failure 1,743 (2) 2,635 (1) 29 (1) 38 (0) 41 (1) 76 (<0.1) 1,813 (2) 2,749 (1) 
Angina 6,529 (8) 12,975 (4) 48 (1) 93 (1) 196 (3) 440 (2) 6,773 (8) 13,508 (4) 
Stroke 4,014 (5) 9,521 (3) 105 (3) 198 (1) 111 (2) 275 (1) 4,230 (5) 9,994 (3) 
Any CVD 15,769 (20) 33,155 (11) 225 (6) 443 (3) 519 (7) 1,101 (4) 16,513 (18) 34,699 (10) 
Hypertension 33,234 (42) 62,749 (20) 1,419 (35) 2,852 (17) 1,803 (25) 2,941 (10) 36,456 (40) 68,542 (19) 
Anti-hyperglycaemic drugs 
(Ever prescribed)*         
None 10,767 (14) 317,080 (100) 294 (7) 16,460 (100) 536 (7) 29,008 (100) 11,597 (13) 362,548(100) 
Insulin 17,693 (22)  917 (22)  1,381 (19)  19,991 (22)  
Biguanides 62,598 (79)  3,530 (86)  6,324 (87)  72,452 (80)  
Sulphonylureas 38,281 (48)  2,090 (51)  3,739 (52)  44,110 (49)  
Thiazolidinedione  14,481 (18)  622 (15)  1,411 (20)  16,514 (18)  
GLP1-RA 3,769 (5)  117 (3)  225 (3)  4,111 (5)  
DPP-4 11,078 (14)  633 (15)  1,231 (17)  12,942 (14)  
Alpha glucosidase 1,545 (2)  58 (1)  117 (2)  1,720 (2)  
SGLT2 615 (1)  21 (1)  59 (1)  695 (1)  
Metglinides 902 (1)  58 (1)  100 (1)  1,060 (1)  
Other  medications (Ever 
prescribed) *         
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Antihypertensive 3,577 (5) 7,496 (2) 173 (4) 390 (2) 145 (2) 320 (1) 3,895 (4) 8,206 (2) 
Diuretics 20,688 (26) 41,226 (13) 585 (14) 1,421 (9) 684 (9) 1,508 (5) 21,957 (24) 44,155 (12) 
Beta blockers 18,938 (24) 42,580 (13) 427 (10) 1,103 (7) 758 (11) 1,913 (7) 20,123 (22) 45,596 (13) 
Calcium blockers 15,070 (19) 30,059 (10) 724 (18) 1,588 (10) 703 (10) 1,386 (5) 16,497 (18) 33,033 (9) 
Statins 19,376 (24) 35,419 (11) 627 (15) 811 (5) 1,219 (17) 1,679 (6) 21,222 (23) 37,909 (11) 
Ace inhibitors 17,145 (22) 30,152 (10) 558 (14) 889 (5) 823 (11) 1,370 (5) 18,526 (20) 32,411 (9) 
CPMs 34,595 (44) 73,919 (23) 1,272 (31) 2,473 (15) 1,997 (28) 3,671 (13) 37,864 (42) 80,063 (22) 
Anti-depressants 17,419 (22) 54,807 (17) 393 (10) 1,413 (9) 926 (13) 3,025 (10) 18,738 (21) 59,245 (16) 
Anti-obesity 3,213 (4) 2,940 (1) 121 (3) 171 (1) 200 (3) 229 (1) 3,534 (4) 3,340 (1) 
 
*: n (%);  
†: mean ± SD; 
‡: median (Q1, Q3) 
§: Not presented for control subjects 
BMI: Body mass index; 
SPB: Systolic blood pressure;  
LDL-C: Low density lipoprotein cholesterol; 
HDL-C: High density lipoprotein cholesterol; 
CKD: Chronic kidney disease; 
Any CVD: Defined as the occurrence of angina or myocardial infarction or coronary artery disease (including bypass surgery and angioplasty) or heart failure 
or stroke before diagnosis 
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Table 2:  Mean ± SD of BMI in three ethnic groups at the time of diagnosis of T2DM, by different age groups at diagnosis among patients 
diagnosed from 01 Jan 2006. The p values are estimated to present the significance of differences in the distribution of BMI between each 
combination of two ethnic groups. The proportions of patients under different obesity grades are presented by number (%).  
   Absolute difference in mean (p-value) BMI categories* 
 n BMI† WE Vs SA WE Vs AC AC Vs SA Grade 1 Obese Grade 2 Obese Grade 3 Obese 
Age group: ≤ 40 years         
White European 2051 36.3 ± 8.6 6.6 (<0.001) 5.2(<0.001) 1.4 (<0.022) 509 (24) 468 (23) 615 (30) 
African-Caribbean  311 31.1 ± 6.5    89 (29) 43 (14) 28 (9) 
South Asian 892 29.8 ± 6.2    212 (24) 90 (10) 64 (7) 
Age group: 41-50 years         
White European 5717 35.1 ± 7.4 5.3 (<0.001) 3.6 (<0.001) 2.1 (<0.001) 1635 (29) 1360 (24) 1263 (22) 
African-Caribbean  716 31.5 ± 6.3    215 (30) 128 (18) 57 (8) 
South Asian 1092 29.4 ± 5.8    278 (26) 109 (10) 44 (4) 
Age group: 51-60 years         
White European 7907 33.4 ± 6.7 3.8 (<0.001) 2.2 (<0.001) 1.6 (<0.001) 2537 (32) 1644 (21) 1139 (14) 
African-Caribbean  497 31.2 ± 6.2    132 (27) 82 (17) 43 (9) 
South Asian 679 29.6 ± 5.7    167 (25) 73 (11) 27 (4) 
Age group: 61-70 years         
White European 8487 32.1 ± 6.2 3.5 (<0.001 1.1 (<0.038) 2.3 (<0.001) 2849 (34) 1446 (17) 824 (10) 
African-Caribbean  188 30.9 ± 5.4    65 (35) 27 (14) 12 (6) 
South Asian 264 28.6 ± 5.4    56 (21) 21 (8) 9 (3) 
Age group: 70+ years         
White European 5198 30.2 ± 5.4 2.7 (<0.001) 0.44 (1.000) 2.3 (0.015) 1554 (30) 637 (12) 255 (5) 
African-Caribbean  80 29.7 ± 6.6    19 (24) 9 (11) 8 (10) 
South Asian 100 27.4 ± 5.5    18 (18) 8 (8) 3 (3) 
Female         
White European 12,292 33.9 ± 7.7 3.4 (<0.001) 0.6 (0.051) 2.8 (<0.001) 3414 (28) 2534 (21) 2328 (19) 
African-Caribbean  823 33.3 ± 6.4    265 (32) 194 (24) 107 (13) 
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South Asian 1303 30.5 ± 6.0    344 (26) 193 (15) 86 (7) 
Male         
White European 17068 32.3 ± 6.2 3.7 (<0.001) 2.8 (<0.001) 0.9 (0.002) 5,670 (33) 3,012 (16) 1768 (10) 
African-Caribbean  969 29.5 ± 5.4    255 (26) 95 (10) 41 (4) 
South Asian 1724 28.6 ± 5.6    387 (22) 108 (6) 61 (4) 
         
 
*: n (%);  
†: mean ± SD; 
WE: White European;  
SA: South Asian;  
AC: African-Caribbean 
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FIGURES 
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